Immunomodulation as A Treatment to Breast Cancer
DOI:
https://doi.org/10.54097/ajst.v2i1.938Keywords:
Therapy, Breast cancer, Treatment, Immunomodulation, Immune therapy.Abstract
In recent years, breast cancer has been the leading cause of cancer death among women. Researchers are leading studies related to the breast cancer to help with progress of our understanding of cancer and exploring more efficient and less toxic therapies. Increased public awareness and advances in the preclinical proof of feasibility and clinical confirmation of have led to earlier diagnosis and novel curative therapies. Immunomodulation is an emerging treatment, which enhance the immunity against cancer cells through releasing various cytokines, expanding to gene-based treatments. Therefore, this work reviews the immunomodulation approach and its potential application when combined with other therapies (oncolytic virotherapy, radiotherapy, physical therapy).
Downloads
References
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.
Leroy, P., et al. 1998. Cancer immunotherapy by direct in vivo transfer of immunomodulatory genes. Res. Immunol. 149:681–684.
Fearon, E.R., et al. 1990. Interleukin-2 production by tumor cells bypass- es T helper function in the generation of an antitumor response. Cell. 60:397–403.
Viret, C., and Lindemann, A. 1997. Tumor immunotherapy by vaccination with cytokine gene transfected cells. Int. Rev. Immunol. 14:193–212.
Golumbek, P.T., et al. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 254:713–716.
Maroun J, Munoz-Alia M, Ammayappan A, Schulze A, Peng KW, Russell S. Designing and building oncolytic viruses. Future Virol. (2017) 12:193–213. doi: 10.2217/fvl-2016-0129
Poh A. First oncolytic viral therapy for melanoma. Cancer Discov. (2016) 6:6. doi: 10.1158/2159-8290.CD-NB2015-158
Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, et al. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther. (2012) 20:749–58. doi: 10.1038/mt.2011.276
Jaffray DA. Image-guided radiotherapy: from current concept to future perspectives. Nat Rev Clin Oncol. (2012) 9:688–99. doi: 10.1038/nrclinonc.2012.194
NCT01642290
Locy H, de Mey S, de Mey W, De Ridder M, Thielemans K, Maenhout SK. Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend. Front Immunol. 2018 Dec 11;9:2909. doi: 10.3389/fimmu.2018.02909. PMID: 30619273; PMCID: PMC6297829.
Sersa G, Miklavcic D. Electrochemotherapy of tumours. J Vis Exp. (2008) 22:1038. doi: 10.3791/1038
Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours. Eur J Surg. (2007) 34:232–43. doi: 10.1016/j.ejso.2007.05.016
Schmidt G, Juhasz-Boss I, Solomayer E-F, Herr D. Electrochemotherapy in breast cancer: a review of references. Geburtshilfe Frauenheilkd (2014) 74:557–62. doi: 10.1055/s-0034-1368538
Downloads
Published
Issue
Section
How to Cite
